TRDA
Zeiher Bernhardt G, TRDA's Director, spent $29.3K of their own money on 5,000 shares at $6, opening a brand-new position.
+$29.3K
5,000 sh @ $6
TRDA
Entrada Therapeutics, Inc.
SEC CIK 1689375
$6.46
−40.3% · 90 days
90-day buys
$29.3K
1 open-market
90-day sells
$661.1K
3 open-market
Net insider flow
−$631.8K
Net selling
Filings shown
61
Most recent
Advertisement
At a glance
Over the last 90 days, insiders at TRDA have sold a net $631.8K of stock (1 open-market buy vs 3 sells).
Largest recent trade: Parmar Kush sold $1.76M of TRDA, trimming their stake 6%.
Most active filer: Baker Bros. Advisors Lp, with 16 transactions among the recent filings shown.
Insider transaction history
Form 4 filings for TRDA, newest firstTRDA
−$398.8K
25,907 sh @ $15
TRDA
+$26.1K
15,000 sh @ $2
TRDA
−$230K
15,000 sh @ $15
TRDA
−$32.4K
2,500 sh @ $13
Advertisement
TRDA
−$155.2K
11,894 sh @ $13
TRDA
−$148.2K
11,388 sh @ $13
TRDA
−$40.6K
3,116 sh @ $13
TRDA
−$66.2K
5,089 sh @ $13
TRDA
−$97.9K
7,988 sh @ $12
TRDA
−$225.5K
19,181 sh @ $12
TRDA
−$67.2K
5,712 sh @ $12
TRDA
−$165K
14,038 sh @ $12
TRDA
−$89.1K
7,577 sh @ $12
TRDA
−$115.1K
9,869 sh @ $12
TRDA
−$34.3K
2,939 sh @ $12
TRDA
−$84.2K
7,223 sh @ $12
TRDA
−$45.4K
3,898 sh @ $12
TRDA
+$0
139,400 sh
TRDA
+$0
44,600 sh
TRDA
+$0
55,800 sh
TRDA
+$0
55,800 sh
TRDA
−$88.9K
8,910 sh @ $10
TRDA
Baker Bros. Advisors Lp, TRDA's 10% owner, spent $11K of their own money on 1,213 shares at $9.
+$11K
1,213 sh @ $9
TRDA
Baker Bros. Advisors Lp, TRDA's 10% owner, spent $121.4K of their own money on 13,386 shares at $9.
+$121.4K
13,386 sh @ $9
TRDA
Baker Bros. Advisors Lp, TRDA's 10% owner, spent $10.8K of their own money on 1,186 shares at $9.
+$10.8K
1,186 sh @ $9
TRDA
Baker Bros. Advisors Lp, TRDA's 10% owner, spent $118.7K of their own money on 13,082 shares at $9.
+$118.7K
13,082 sh @ $9
TRDA
−$1.76M
200,000 sh @ $9
TRDA
−$1.76M
200,000 sh @ $9
TRDA
Baker Bros. Advisors Lp, TRDA's 10% owner, spent $56.6K of their own money on 7,321 shares at $8, growing their stake 2%.
+$56.6K
7,321 sh @ $8
Advertisement
About TRDA insider activity
This page tracks every recent Form 4 filed for Entrada Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.
The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.
Frequently asked questions
How often is TRDA insider data updated?
Continuously. We read from SEC EDGAR, so new Form 4 filings for Entrada Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.
What does "net insider flow" mean?
It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.
Why do some rows show grants or option exercises instead of buys?
Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.
Is this investment advice?
No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.